3 minutes with Mark Denham, Head of European Equities at Carmignac
Architas' Jon Arthur and Avni Thakrar explain why investors are increasingly turning to alternative assets
Partner Insight: Alternative assets: which have the potential to be true diversifiers for investors?
With so many alternatives options available, Solomon Nevins, Senior Investment Manager at Architas, weighs up the options
With the size of the alternative investments sector predicted to reach $14 trillion by 2023, we review which asset classes and strategies fall under the heading of alternatives - and what investors need to be aware of
Vibrating pillows and flashing lights: HSBC GAM's Tim Roberts shares his story on living with deafness
Improving accessibility for deaf employees
Nick Maroutsos, Co-Head of Global Bonds at Janus Henderson, explains what he sees as the major factors influencing investors' decisions in 2019
Managed fund since 2017
Besides Brexit, David Cumming, Aviva's chief investment officer for equities, identifies two other major macroeconomic influencers that might impact the UK
Aviva Investors' chief investment officer for equities, David Cumming, discusses how his team have integrated ESG factors into their decision-making process
David Cumming, Aviva Investors' chief investment officer for equities, remains positive about UK stocks despite a pummelling in 2018
Partner Insight: For Blackfinch, the arrival of its IHT portfolio services was a 'natural evolution' in the group's offering and points to an established track record of returning cash to investors.
Exploring neurodiversity in the workplace
Partner Insight: Isaac Chebar, manager of the DNCA European Select Equity Fund, on how a contrarian view allows him to seek out undervalued equities in continental Europe.
Partner Insight: Isaac Chebar, manager of the DNCA European Select Equity Fund, discusses why big box retailers shouldn't be discounted - despite the growing number of e-commerce upstarts
Partner Insight: Isaac Chebar, manager of the DNCA European Select Equity Fund, discusses the opportunities available in pharma, telecoms and energy
Partner insight: There was a positive flow of capital into the biotech sector during the third quarter.BB Biotech is actively increasing its exposure to new drug development technology such as RNA-based therapeutic agents, and gene and cell-based therapies....